<p>精密科学（EXAS）本月悄然成为诊断领域中表现较强的股票之一，随着投资者关注其收入增长改善和癌症检测亏损缩小，股价大幅攀升。</p>
<p>查看我们对精密科学的最新分析。</p>
<p>在过去 30 天内，股价回报率超过 50% 的大幅上涨，建立在强劲的 90 天涨幅和 67% 的年度总股东回报之上。这清楚地表明，尽管仍然处于亏损状态，市场情绪已转向精密科学的增长故事。</p>
<p>如果精密科学让你重新关注诊断领域，值得通过我们的医疗股票筛选器探索其他医疗公司作为潜在的下一个机会。</p>
<p>在经历强劲上涨后，股票现已接近分析师目标，而公司仍在录得可观亏损，关键问题是精密科学是否仍被低估，还是市场已经在定价其下一阶段的增长。</p>
<h2>最受欢迎的叙述：低估 2%</h2>
<p>精密科学最后收盘价为 101.50 美元，而叙述的公允价值大约为 103.67 美元，这一故事倾向于适度的上行空间，依赖于持续的执行和盈利能力的改善。</p>
<blockquote>
<p><em>多年的运营成本优化计划（目标是到 2026 年通过自动化、人工智能驱动的实验室/流程效率和减少一般管理费用实现每年节省 1.5 亿美元）正在为未来扩大 EBITDA 和净利润率奠定基础，尤其是在规模效应显现时。</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>想知道利润预计比销售增长得快多少，以及这对仍处于亏损状态的癌症专家意味着什么样的未来倍数吗？这个叙述依赖于从深度亏损到健康利润率的激进转变，以及通常只为更成熟公司保留的溢价估值。想知道哪些具体的盈利和利润率目标必须落实，以维持这一公允价值？继续阅读以解开这一价格背后的完整假设。</p>
<p><strong>结果：公允价值为 103.67 美元（低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，执行远非保证，重研发支出、交易风险和日益激烈的结直肠筛查竞争都可能破坏乐观的盈利路径。</p>
<p>了解精密科学叙述的关键风险。</p>
<h2>自建精密科学叙述</h2>
<p>如果你对这个故事有不同看法，或者想自己深入数字分析，可以在几分钟内构建自定义视图：按你的方式进行。</p>
<p>一个好的起点是我们的分析，强调投资者对精密科学的 3 个关键回报的乐观预期。</p>
<h2>准备好迎接下一个投资机会了吗？</h2>
<p>在动能减弱之前，利用 Simply Wall St 的强大数据驱动股票筛选器锁定符合你策略的新想法。</p>
<ul>
<li>通过这些 908 只基于现金流的低估股票，提前捕捉潜在的错误定价。</li>
<li>通过这 26 只人工智能便士股票，乘上下一波创新浪潮。</li>
<li>通过这 13 只收益率超过 3% 的分红股票，增强你的收入流。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<p>移动基础设施用于国防和灾难</p>
<p>下一波机器人技术不是类人型的，而是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，随处可用。</p>
<p>在下一轮合同之前获取投资者简报</p>
<p>由 CiTech 赞助</p>

精密科学

<p>精密科学（EXAS）股价大幅上涨，30 天回报超过 50%。尽管盈利表现不佳，但由于收入增长和亏损缩小，市场情绪依然积极。分析师认为该股票低估 2%，合理价值为 103.67 美元。运营成本优化措施旨在改善利润率。风险包括高额的研发支出和竞争压力。投资者被鼓励关注医疗保健股票以寻找潜在机会</p>

<p>Exact Sciences (EXAS) has quietly become one of the stronger movers in diagnostics this month, with shares climbing sharply as investors focus on its improving revenue growth and narrowing losses in cancer testing.</p>
<div class="lb-trans"><p>精密科学（EXAS）本月悄然成为诊断领域中表现较强的股票之一，随着投资者关注其收入增长改善和癌症检测亏损缩小，股价大幅攀升。</p>
</div><p>See our latest analysis for Exact Sciences.</p>
<div class="lb-trans"><p>查看我们对精密科学的最新分析。</p>
</div><p>That sharp 30 day share price return of over 50 percent builds on a powerful 90 day gain and a 67 percent one year total shareholder return. This is a clear sign that sentiment has swung toward Exact Sciences growth story despite its still negative earnings.</p>
<div class="lb-trans"><p>在过去 30 天内，股价回报率超过 50% 的大幅上涨，建立在强劲的 90 天涨幅和 67% 的年度总股东回报之上。这清楚地表明，尽管仍然处于亏损状态，市场情绪已转向精密科学的增长故事。</p>
</div><p>If Exact Sciences has put diagnostics back on your radar, it is worth exploring other healthcare names using our screener for healthcare stocks as potential next wave opportunities.</p>
<div class="lb-trans"><p>如果精密科学让你重新关注诊断领域，值得通过我们的医疗股票筛选器探索其他医疗公司作为潜在的下一个机会。</p>
</div><p>With the stock now near analyst targets after a powerful run and the business still posting sizable losses, the key question is whether Exact Sciences remains undervalued or if the market is already pricing in its next leg of growth.</p>
<div class="lb-trans"><p>在经历强劲上涨后，股票现已接近分析师目标，而公司仍在录得可观亏损，关键问题是精密科学是否仍被低估，还是市场已经在定价其下一阶段的增长。</p>
</div><h2>Most Popular Narrative: 2% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：低估 2%</h2>
</div><p>With Exact Sciences last closing at $101.50 against a narrative fair value of roughly $103.67, the story leans toward modest upside that hinges on sustained execution and improving profitability.</p>
<div class="lb-trans"><p>精密科学最后收盘价为 101.50 美元，而叙述的公允价值大约为 103.67 美元，这一故事倾向于适度的上行空间，依赖于持续的执行和盈利能力的改善。</p>
</div><blockquote>
<p><em>Multi-year operational cost optimization initiatives (targeting $150M in annual savings by 2026 via automation, AI-driven lab/process efficiencies, and reduced G&amp;A spend) are establishing a foundation for expanding EBITDA and net margins over time, especially as scale effects take hold.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>多年的运营成本优化计划（目标是到 2026 年通过自动化、人工智能驱动的实验室/流程效率和减少一般管理费用实现每年节省 1.5 亿美元）正在为未来扩大 EBITDA 和净利润率奠定基础，尤其是在规模效应显现时。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>Want to see how much faster profits are expected to grow than sales, and what kind of future multiple that implies for a still unprofitable cancer specialist? The narrative leans on an aggressive swing from deep losses to healthy margins, plus a premium valuation usually reserved for more mature names. Curious which specific earnings and margin targets have to fall into place for this fair value to hold up? Read on to unpack the full set of assumptions behind that price.</p>
<div class="lb-trans"><p>想知道利润预计比销售增长得快多少，以及这对仍处于亏损状态的癌症专家意味着什么样的未来倍数吗？这个叙述依赖于从深度亏损到健康利润率的激进转变，以及通常只为更成熟公司保留的溢价估值。想知道哪些具体的盈利和利润率目标必须落实，以维持这一公允价值？继续阅读以解开这一价格背后的完整假设。</p>
</div><p><strong>Result: Fair Value of $103.67 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 103.67 美元（低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, execution is far from guaranteed, with heavy R&amp;D spending, deal risk, and intensifying colorectal screening competition all capable of derailing the optimistic earnings path.</p>
<div class="lb-trans"><p>然而，执行远非保证，重研发支出、交易风险和日益激烈的结直肠筛查竞争都可能破坏乐观的盈利路径。</p>
</div><p>Find out about the key risks to this Exact Sciences narrative.</p>
<div class="lb-trans"><p>了解精密科学叙述的关键风险。</p>
</div><h2>Build Your Own Exact Sciences Narrative</h2>
<div class="lb-trans"><h2>自建精密科学叙述</h2>
</div><p>If you see the story differently or want to dig into the numbers yourself, you can build a custom view in just minutes: Do it your way.</p>
<div class="lb-trans"><p>如果你对这个故事有不同看法，或者想自己深入数字分析，可以在几分钟内构建自定义视图：按你的方式进行。</p>
</div><p>A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Exact Sciences.</p>
<div class="lb-trans"><p>一个好的起点是我们的分析，强调投资者对精密科学的 3 个关键回报的乐观预期。</p>
</div><h2>Ready for your next investing edge?</h2>
<div class="lb-trans"><h2>准备好迎接下一个投资机会了吗？</h2>
</div><p>Before momentum cools, put Simply Wall St to work and lock in fresh ideas that match your strategy using our powerful, data driven stock screener.</p>
<div class="lb-trans"><p>在动能减弱之前，利用 Simply Wall St 的强大数据驱动股票筛选器锁定符合你策略的新想法。</p>
</div><ul>
<li>Capture potential mispricings early by targeting companies that look cheap on future cash flows through these 908 undervalued stocks based on cash flows.</li>
<li>Ride the next wave of innovation by focusing on early stage disruptors with these 26 AI penny stocks.</li>
<li>Strengthen your income stream by filtering for reliable payers via these 13 dividend stocks with yields &gt; 3%.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过这些 908 只基于现金流的低估股票，提前捕捉潜在的错误定价。</li>
<li>通过这 26 只人工智能便士股票，乘上下一波创新浪潮。</li>
<li>通过这 13 只收益率超过 3% 的分红股票，增强你的收入流。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，性质为一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移动基础设施用于国防和灾难</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波机器人技术不是类人型的，而是完全自主的塔楼，在 30 分钟内提供 5G、ISR 和雷达服务，随处可用。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一轮合同之前获取投资者简报</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 赞助</p>
</div>

在精密科学（EXAS）最近股价飙升后，它是否仍然被低估？